Fig. 4From: A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitusChanges from baseline in HbA1c over time; filled circle omarigliptin 25 mg q.w., open circle placeboBack to article page